Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Marky1on Jan 16, 2020 2:19pm

162 Views

Post# 30561381

RE:RE:RE:RE:RE:RE:RE:Hope this McWhirter pick does better than his other one

Thanks buddy! Glad that we are in the same boat! Just can't understand why investors can't see what an amazing new invention 346 is and how it's going to revolutionize the entire NSAIDS industry.
i have a sell order for $5.00 CDN and I ain't changing it...If ASLN can go from 38 cents usd to $8.00 in 5 days we could also!!
GLTA all the smart people here!

Bullboard Posts

Changing Europe’s dependency on HREE from China